Xeno Biosciences - About the company
Xeno Biosciences is a deadpooled company based in Cambridge (United States), founded in 2015 by Hasan Celiker. It operates as a Developer of transformational therapies for metabolic diseases. Xeno Biosciences has raised $8.42M in funding from Boston Harbor Angels. The company has 156 active competitors, including 55 funded and 45 that have exited. Its top competitors include companies like Rhythm Pharmaceuticals, MannKind Corp and Adocia.
Company Details
Developer of transformational therapies for metabolic diseases. The lead product of the company is XEN-101 an oral formulation, engineered to produce weight loss by mimicking the microbiome changes induced by gastric bypass surgery.
Key Metrics
Founded Year
2015
Location
Cambridge, United States
Stage
Deadpooled
Total Funding
$8.42M in 4 rounds
Latest Funding Round
Investors
Ranked
79th among 156 active competitors
Employee Count
3 as on Apr 30, 2026
Sign up to download Xeno Biosciences' company profile
Xeno Biosciences's funding and investors
Xeno Biosciences has raised a total funding of $8.42M over 4 rounds. Its first funding round was on Jul 05, 2018. Xeno Biosciences has 8 institutional investors.
Here is the list of recent funding rounds of Xeno Biosciences:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 05, 2023 | 2286865 | Conventional Debt | 9422007 | 3982627 | 8127809 | 8516448 |
2021 | 9256 | Series A | 4423 | 9369 | 2323 | |
Feb 08, 2019 | 1489208 | Seed | 4494431 | 9268162 | 3268455 | 3312020 |
Access funding benchmarks and valuations. Sign up today!View details of Xeno Biosciences's funding rounds and investors
Xeno Biosciences' founders and board of directors
Founder? Claim ProfileThe founders of Xeno Biosciences is Hasan Celiker.
Here are the details of Xeno Biosciences' key team members:
- Hasan Celiker: Founder & CEO of Xeno Biosciences.
View details of Xeno Biosciences's Founder profiles and Board Members
Xeno Biosciences' employee count trend
Xeno Biosciences has 3 employees as of Apr 26. Here is Xeno Biosciences's employee count trend over the years:
Uncover Xeno Biosciences' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Xeno Biosciences's Competitors and alternates
Top competitors of Xeno Biosciences include Rhythm Pharmaceuticals, MannKind Corp and Adocia. Here is the list of Top 10 competitors of Xeno Biosciences, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Rhythm Pharmaceuticals 2010, Boston (United States), Public | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | $84M | 70/100 | |
2nd | MannKind Corp 1991, Los Angeles (United States), Public | Developer of small-molecule drugs | $50M | 70/100 | |
3rd | Developer of therapeutics for the treatment of diabetes and obesity | $26M | 69/100 | ||
4th | Corcept 1998, Menlo Park (United States), Public | Developer of cortisol modulators for the treatment of various diseases | - | 68/100 | |
5th | MeiraGTx 2015, New York City (United States), Public | Developer of gene therapies for ocular and neurodegenerative diseases | - | 65/100 | |
6th |  89bio 2018, San Francisco (United States), Acquired | Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders | $60M | 64/100 | |
7th |  D&D Pharmatech 2014, Seongnam-si (South Korea), Public | Developer of GLP-1-based therapeutics for metabolic disease treatment | $205M | 64/100 | |
8th |  Rani Therapeutics 2012, San Jose (United States), Public | Developer of technology for the oral delivery of large drug molecules | $226M | 63/100 | |
9th |  Enveda 2019, Boulder (United States), Series D | AI-based platform to decipher the chemistry of nature and develop new medicines | $517M | 63/100 | |
10th |  BioAge Labs Emeryville (United States), Public | Provider of a bioinformatics platform for biomarkers and drug discovery | $294M | 62/100 | |
79th | Xeno Biosciences 2015, Cambridge (United States), Deadpooled | Developer of transformational therapies for metabolic diseases | $8.42M | 35/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Xeno Biosciences's competitors? Click here to see the top ones
Xeno Biosciences's Investments and acquisitions
Xeno Biosciences has made no investments or acquisitions yet.
Reports related to Xeno Biosciences
Here is the latest report on Xeno Biosciences's geography:
News related to Xeno Biosciences
•
•
Xeno Biosciences Starts Phase 1b Proof-of-Concept Study in ObesityBusiness Wire•Jun 26, 2024•Xeno Biosciences
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Xeno Biosciences
Explore our recently published companies
- Saalfo Tech - Mysuru based, 1990 founded, Unfunded company
- Tolia - Thane based, 1979 founded, Unfunded company
- Uvtcpl - India based, Unfunded company
- Diamondexch99 - Unfunded company
- Krishna's Herbal & Ayurveda - Jodhpur based, 2007 founded, Funding Raised company
- Dash - Atlanta based, 2025 founded, Unfunded company
